Companies · Pharmaceuticals

Sen-Jam Pharmaceutical Llc

HUNTINGTON · Pharmaceuticals

Diligence memoA one-page analyst read on Sen-Jam Pharmaceutical Llc — recommendation, valuation, rhythm, risks.
$480K
Total raised · real
2
Rounds
0.1×
Latest step-up
Top 90%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Sat Apr 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Sen-Jam Pharmaceutical Llc looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.06× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era.
  • Within the normal band (106% of peer median) for its niche.
At-risk
  • Last raise 3.2 yr ago; this sector typically re-raises about every 13 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Sen-Jam Pharmaceutical Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
6.4 yr record
Peak capital year was 2020 with $3.2M across 2 filings.
Market position
ahead of 11% of Pharmaceuticals peers
Capital scale is ahead of 11% of Pharmaceuticals peers; modeled value is above 5% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2020: $3.2M across 2 filings.
  • Largest single filing was $3.0M on 2020-01-28.
  • Filing rows sum to $3.5M, while canonical raised total is $480K; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Sen-Jam Pharmaceutical Llc is one of 1613 Pharmaceuticals companies tracked from HUNTINGTON. By capital raised it ranks in the long tail (ahead of 11% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(c)
Reg D exemption
6
Investors (latest)
2023-04-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2020-01-28 Raised $185K (real) Modeled valuation $8.8M (est)$185K$8.8MPre-Seed2020Seed · 2020-01-28 Raised $3.0M (real) Modeled valuation $114M (est)$3.0M$114MSeed2020Pre-Seed · 2023-04-22 Raised $295K (real) Modeled valuation $2.7M (est)$295K$2.7MPre-Seed2023+$3.0M+$295KCumulative $3.5M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$185K · 2020
Seed$3.0M · 2020
Bridge · Seed-stage$295K · 2023smaller follow-on

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$2.7M
Base estimate est.
$165K
Conservative case
$13.0M
Upside case
$1.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $8.8M · 2020-01-282020Seed · modeled $114.1M · 2020-01-28Pre-Seed · modeled $2.7M · 2023-04-222023
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
3.2 yr
Elapsed time used
3.2 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
19 mo
Avg between rounds
$149K/yr
Capital velocity
6.4 yr
On record since
2020
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$480K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.7× of median
This company$295K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$2.7M
Sector median$76.1M

Raised more than 11% of sector peers (real $). Modeled value above 5% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #17 of 38.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Eleison Pharmaceuticals Inc · Pre-Seed Raised $980K · modeled $15.9M (est)Telomir Pharmaceuticals, Inc. · Pre-Seed Raised $1.0M · modeled $9.7M (est)Drusolv Therapeutics, Inc. · Pre-Seed Raised $500K · modeled $8.5M (est)TF Tech Ventures, Inc. · Pre-Seed Raised $625K · modeled $8.3M (est)Thyron Pharmaceuticals, Inc. · Pre-Seed Raised $500K · modeled $8.2M (est)Gelesis Holdings, Inc. · Pre-Seed Raised $576K · modeled $7.9M (est)MEDPhlow, LLC · Pre-Seed Raised $1.0M · modeled $6.6M (est)Centaur Bio Inc. · Pre-Seed Raised $1.5M · modeled $5.5M (est)7 Hills Pharma Inc. · Pre-Seed Raised $1.0M · modeled $4.9M (est)Artin Bioscience Inc. · Pre-Seed Raised $483K · modeled $4.8M (est)Precision Genetics, Inc. · Pre-Seed Raised $1.0M · modeled $4.8M (est)Zena Therapeutics Inc. · Pre-Seed Raised $500K · modeled $3.8M (est)Sen-Jam Pharmaceutical Llc (this company) Raised $480K · modeled $2.7M (est)Sen-Jam Pharmaceutical Llc
CompanyStageRaised · realValue · estvs peer med.
Eleison Pharmaceuticals IncPre-Seed$980K$15.9M6.25×
Telomir Pharmaceuticals, Inc.Pre-Seed$1.0M$9.7M3.81×
Drusolv Therapeutics, Inc.Pre-Seed$500K$8.5M3.33×
TF Tech Ventures, Inc.Pre-Seed$625K$8.3M3.25×
Thyron Pharmaceuticals, Inc.Pre-Seed$500K$8.2M3.23×
Gelesis Holdings, Inc.Pre-Seed$576K$7.9M3.10×
MEDPhlow, LLCPre-Seed$1.0M$6.6M2.57×
Centaur Bio Inc.Pre-Seed$1.5M$5.5M2.15×
7 Hills Pharma Inc.Pre-Seed$1.0M$4.9M1.94×
Artin Bioscience Inc.Pre-Seed$483K$4.8M1.88×
Precision Genetics, Inc.Pre-Seed$1.0M$4.8M1.87×
Zena Therapeutics Inc.Pre-Seed$500K$3.8M1.50×
Sen-Jam Pharmaceutical Llc this companyPre-Seed$480K$2.7M1.06×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$185K2020-01-28$1.0M$8.8M90%
Seed$3.0M2020-01-28$15.0M$114.1M90%
Pre-Seed$295K2023-04-22$1.6M$2.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$185K2020-01-28
    • First recorded raise — entered as Pre-Seed.
    • 5 investors on this round.
  2. Seed$3.0M2020-01-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 16.2× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 506(c)).
    • 2 investors on this round.
  3. Pre-Seed$295K2023-04-22
    • Raised again after 39 mo — slower than the ~13 mo sector norm.
    • Round 10.2× smaller than the prior — bridge or down round.
    • Switched to Rule 506(c) (was Rule 506(b)).
    • 6 investors on this round.
Intelligence
2024 ~Q4
Modeled next raise · ~19mo cadence
$295K
Modeled next size est.range $295K$472K
0.1×
Last step-up
$149K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jacqueline Iversen2023-04
James 223 Wall Street Iversen2020-01
James Iversen2020-01
Registry & provenance

Sen-Jam Pharmaceutical Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1802249
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Artin Bioscience Inc.PharmaceuticalsPre-Seed$483K$4.8Msame sector · same stage
Chorda Pharma, Inc.PharmaceuticalsPre-Seed$493K$703Ksame sector · same stage
Titan Partners, LlcPharmaceuticalsPre-Seed$498K$11.7Msame sector · same stage
ADVAC Therapeutics IncPharmaceuticalsPre-Seed$500K$885Ksame sector · same stage
Drusolv Therapeutics, Inc.PharmaceuticalsPre-Seed$500K$8.5Msame sector · same stage
Eleos Pharmaceuticals, Inc.PharmaceuticalsPre-Seed$500K$12.1Msame sector · same stage
Flywheel Healthcare LlcPharmaceuticalsPre-Seed$500K$700Ksame sector · same stage
NapaJen Pharma, Inc.PharmaceuticalsPre-Seed$500K$12.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Compassionate Buds, LLCPharmaceuticalsPre-Seed$16.6M78%
Cyto-Sen Therapeutics, Inc.PharmaceuticalsPre-Seed$37.8M77%
Visum Pharma, Inc.PharmaceuticalsSeed$22.9M75%
Sage Therapeutics, Inc.PharmaceuticalsGrowth/Late$20.7B75%
SEngine Precision Medicine, Inc.BiotechnologySeries A$6.0M74%
DTx Pharma, Inc.PharmaceuticalsSeries D+$2.9B74%
DBV Technologies S.A.PharmaceuticalsSeries D+$2.6B73%
60 Degrees Pharmaceuticals, Inc.PharmaceuticalsSeed$3.7M73%
Frequently asked
How much funding has Sen-Jam Pharmaceutical Llc raised?
Sen-Jam Pharmaceutical Llc has raised approximately $480K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Sen-Jam Pharmaceutical Llc's estimated valuation?
Provath's modeled valuation for Sen-Jam Pharmaceutical Llc is approximately $2.7M (modeled range $165K–$13.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Sen-Jam Pharmaceutical Llc at?
Sen-Jam Pharmaceutical Llc's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Sat Apr 22.
What does Sen-Jam Pharmaceutical Llc do and where is it based?
Sen-Jam Pharmaceutical Llc operates in the Pharmaceuticals sector, based in HUNTINGTON.
Explore related

See where Sen-Jam Pharmaceutical Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Sen-Jam Pharmaceutical Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.